Cargando…

The Complementary Effects of Dabigatran Etexilate and Exercise Training on the Development and Stability of the Atherosclerotic Lesions in Diabetic ApoE Knockout Mice

Aim: To determine the complementary effects of dabigatran etexilate (DE), exercise training (ET), and combination (DE + ET) on the development and stability of the atherosclerotic lesions in diabetic apoE knockout (apoE(−/−)) mice. Methods: In 48 male apoE(−/−) diabetic mice, streptozotocin (STZ) wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kadoglou, Nikolaos PE, Stasinopoulou, Marianna, Gkougkoudi, Evangelia, Christodoulou, Eirini, Kostomitsopoulos, Nikolaos, Valsami, Georgia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609840/ https://www.ncbi.nlm.nih.gov/pubmed/37895867 http://dx.doi.org/10.3390/ph16101396

Ejemplares similares

The Complementary Effects of Atorvastatin and Exercise Treatment on the Composition and Stability of the Atherosclerotic Plaques in ApoE Knockout Mice
por: Moustardas, Petros, et al.
Publicado: (2014)

The Discovery of Dabigatran Etexilate
por: van Ryn, Joanne, et al.
Publicado: (2013)

Dabigatran etexilate tetrahydrate
por: Liu, Hong-Qiang, et al.
Publicado: (2012)

Exercise-Induced Pulmonary Hypertension: A Valid Entity or Another Factor of Confusion?
por: Khattab, Elina, et al.
Publicado: (2023)

New options with dabigatran etexilate in anticoagulant therapy
por: Maegdefessel, Lars, et al.
Publicado: (2010)

Dabigatran-etexilate: Lack of efficacy: case report
Publicado: (2021)

Effects of Long-term Thrombin Inhibition (Dabigatran Etexilate) on Spontaneous Thrombolytic Activity during the Progression of Atherosclerosis in ApoE(−/−)–LDLR(−/−) Double-Knockout Mice
por: Sanda, Tomohide, et al.
Publicado: (2020)

Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice
por: Preusch, Michael R, et al.
Publicado: (2015)

Pulmonary Hypertension in Left Ventricular Valvular Diseases: A Comprehensive Review on Pathophysiology and Prognostic Value
por: Velidakis, Nikolaos, et al.
Publicado: (2023)

Recovery of Visual Function after Administration of Dabigatran Etexilate
por: Schönfeld, Carl-Ludwig, et al.
Publicado: (2014)

Dabigatran etexilate: Cholestatic liver injury: case report
Publicado: (2021)

A Comprehensive Review of the Cardiovascular Protective Properties of Silibinin/Silymarin: A New Kid on the Block
por: Kadoglou, Nikolaos P. E., et al.
Publicado: (2022)

Systemic Lupus Erythematosus and Pulmonary Hypertension
por: Parperis, Konstantinos, et al.
Publicado: (2023)

Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
por: Huber, K, et al.
Publicado: (2013)

The effects of dabigatran etexilate on fracture healing in rats: An experimental study
por: Kerimoglu, Servet, et al.
Publicado: (2015)

Hemopericardium and Cardiac Tamponade in a Patient Treated with Dabigatran Etexilate
por: Kızılırmak, Filiz, et al.
Publicado: (2016)

Potential Pharmaceutical Applications of Quercetin in Cardiovascular Diseases
por: Papakyriakopoulou, Paraskevi, et al.
Publicado: (2022)

The anti-inflammatory effects of exercise training promote atherosclerotic plaque stabilization in apolipoprotein E knockout mice with diabetic atherosclerosis
por: Kadoglou, N.P.E., et al.
Publicado: (2013)

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile
por: Clemens, Andreas, et al.
Publicado: (2012)

Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate
por: Bellamy, L, et al.
Publicado: (2009)

The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients
por: Ellis, Christopher R, et al.
Publicado: (2013)

The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency
por: Gribkova, Irina V., et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
por: Härtter, Sebastian, et al.
Publicado: (2012)

What neurosurgeons need to know about dabigatran etexilate (pradax(®)/pradaxa(®)/prazaxa(®))
por: Dwyer, Christopher Michael, et al.
Publicado: (2015)

The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice
por: Brent, Mikkel Bo, et al.
Publicado: (2017)

In Vitro Selection of Specific DNA Aptamers Against the Anti-Coagulant Dabigatran Etexilate
por: Aljohani, Maher M., et al.
Publicado: (2018)

Extremely Elevated International Normalized Ratio in a Patient with Dabigatran Etexilate Use
por: Memon, Waqas, et al.
Publicado: (2019)

Apixaban/dabigatran etexilate/enoxaparin sodium: Various toxicities: 8 case reports
Publicado: (2022)

Rhabdomyolysis happened after the start of dabigatran etexilate treatment: A case report
por: Zheng, Tingting, et al.
Publicado: (2022)

Estimation Based on Emission Wavelength of Dabigatran Etexilate Mesylate in Bulk and Capsule Dosage Form
por: Anumolu, P. D., et al.
Publicado: (2016)

Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation
por: Simpson, Bryan H., et al.
Publicado: (2019)

FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation
por: J, Aalbers, et al.
Publicado: (2010)

Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling
por: Wang, Nan, et al.
Publicado: (2020)

Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation
por: Liu, Ya-ou, et al.
Publicado: (2022)

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
por: Kansal, Anuraag R, et al.
Publicado: (2012)

Oral Thromboprophylaxis Following Total Hip or Knee Replacement: Review and Multicentre Experience with Dabigatran Etexilate
por: Kendoff, D, et al.
Publicado: (2011)

Adverse events in patients initiated on dabigatran etexilate therapy in a pharmacist-managed anticoagulation clinic
por: Donaldson, Mark, et al.
Publicado: (2013)

Impact of Pharmacists’ audit on improving the quality of prescription of dabigatran etexilate methanesulfonate: a retrospective study
por: Shimizu, Teppei, et al.
Publicado: (2017)

Myotonic dystrophy type 1 and pulmonary embolism: successful thrombus resolution with dabigatran etexilate therapy
por: GALLINORO, EMANUELE, et al.
Publicado: (2018)

Choice of Renal Function Estimator Influences Adverse Outcomes with Dabigatran Etexilate in Patients with Atrial Fibrillation
por: Simpson, Bryan H., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_crpniiuphcg0rvl5ns2fevdlf3